The probiotic company that reads your gut before it fills a capsule.
The wordmark of a lab that treats your gut like a genome to be read - one stool sample, 23,000 possible microbes, and a formula built for exactly one person: you.
There is a quiet absurdity at the center of the probiotic aisle, and Floré is a company organized entirely around noticing it. The same bottle - the same fixed roster of bacterial strains, the same cheerful claims - is sold to millions of people whose guts have almost nothing in common. It is, if you think about it the way a genomicist would, a bit like selling everyone the same prescription glasses and calling it personalized vision. Floré's founder thought about it exactly that way, because he used to sequence human genomes for a living.
Floré is the consumer brand of Sun Genomics, a San Diego biotech started in 2016 by Suneer "Sunny" Jain. Before this, Jain spent seven years at Illumina, where he was part of the team that stood up the company's first clinical services laboratory and, in a CLIA-certified, CAP-accredited setting, helped sequence a whole human genome. He had earlier done clinical patient testing at LabCorp. So when he looked at the probiotic category, he did not see a wellness product. He saw a measurement problem that nobody was bothering to measure.
The Floré process is unglamorous in the way good science usually is. You provide an at-home stool sample. An accredited lab runs whole-genome shotgun metagenomics on it - not the cheaper, blurrier genus-level snapshot that many microbiome tests use, but a strain-level read capable of detecting more than 23,000 microbes: bacteria, fungi, yeast, parasites, viruses. Then an algorithm trained on tens of thousands of prior formulations and a decade of outcome data matches your specific gut against what has worked before, and builds a formula. It can pull from bacterial strains, dozens of prebiotics, and - unusually for a consumer product - targeted bacteriophages, viruses used to knock down the microbes you have too much of.
That last detail is worth sitting with, because it inverts the usual pitch. Most gut-health marketing is additive: take more of the good stuff. Floré's premise is that a healthy microbiome sometimes requires subtraction, and that you cannot know what to subtract until you have read the system. The company frames the whole arrangement not as a product but as a loop - sequence, formulate, re-test, refine - which is also why it sells a subscription that changes the formula over time rather than an auto-ship that never does.
None of this is cheap to run, and Floré does not pretend otherwise. Plans land somewhere around $89 to $110 a month depending on length, bundling the test with recurring shipments. The bet is that people who have cycled through shelf probiotics without result will pay for the thing the shelf cannot offer: a formula addressed to them by name, backed by a lab bill.
A stool sample is sequenced with whole-genome shotgun metagenomics, reading your microbiome down to the species and strain level across 23,000+ possible organisms.
Your data is matched against 40,000+ prior formulations and a decade of IRB-gathered outcomes to build a precise, multi-strain formula - bacteria, prebiotics, even bacteriophages.
You take it daily, track how you respond, and re-test over time so the formula updates as your gut changes. The product is a loop, not a fixed blend.
A molecular and microbiology specialist with a master's in anatomy and cell biology, Jain did clinical patient testing at LabCorp and spent seven years at Illumina - where he helped establish the clinical services lab and sequenced a whole human genome in a CLIA/CAP setting. He put the company through SOSV's IndieBio accelerator, then spent the years since arguing, with data, that gut health should be measured before it is sold.
Custom multi-strain formulas built from your sequencing data, delivered as a re-testing subscription that updates over time.
At-home stool kit processed via whole-genome shotgun metagenomics in an accredited CLIA/CAP lab, resolved to the strain level.
Pre-formulated, system-matched probiotics for people who want a targeted blend without taking the individual test first.
A provider platform that lets clinicians order microbiome analysis and prescribe personalized formulations for patients.
Precision synbiotic formulations studied in autism-spectrum cohorts with Arizona State University, published in mSystems (2024).
A decade of IRB-gathered outcomes across 200+ conditions - the asset DSM partnered to tap for novel ingredient research.
Sunny Jain launches the company in San Diego to bring clinical-grade sequencing to gut health.
The company goes through the SOSV / IndieBio accelerator and introduces its consumer brand, Floré.
Pangaea Ventures leads, with Danone Manifesto Ventures, SOSV, Human Longevity and Nascita Ventures participating.
Floré expands its clinician channel and is featured in Forbes and the San Diego Business Journal's SD500.
DSM Venturing partners with Floré on research and ingredient sourcing, tapping its microbiome algorithms.
Floré and Arizona State publish a pilot study in mSystems on precision synbiotics and autism-spectrum gut symptoms.
It sequences your gut microbiome from an at-home stool sample using whole-genome metagenomics, then formulates a personalized probiotic matched to your data and updates it over time.
Suneer "Sunny" Jain, a molecular biologist and former Illumina and LabCorp scientist, founded Sun Genomics in 2016.
Instead of a fixed one-size-fits-all blend, Floré builds each formula from your individual microbiome sequencing, and can include bacteria, prebiotics, and even targeted bacteriophages.
The company has published peer-reviewed work, including a 2024 mSystems pilot study with Arizona State University, though it frames results as early-stage and non-randomized rather than treatment claims.
Plans run roughly $89 to $110 per month depending on length, typically as a subscription that bundles the microbiome test with recurring personalized probiotic shipments.
Profile compiled from public sources including flore.com, Crunchbase, NutraIngredients, GlobeNewswire, Forbes, San Diego Business Journal and Arizona State University. Figures are company-reported or third-party estimates and are approximate. Not medical advice.